ArticleBMJ open gastroenterology2022

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study.

Masamichi Kimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.